Patents by Inventor Shuning GAI

Shuning GAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies recognizing tau
    Patent number: 11958896
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: April 16, 2024
    Assignee: Prothena Biosciences Limited
    Inventors: Robin Barbour, Svetlana Alexander, Mark Renz, Shuning Gai, Tarlochan S. Nijjar, Philip James Dolan, III, Philip Payne
  • Glycotargeting therapeutics
    Patent number: 11666638
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: June 6, 2023
    Assignees: Ecole Polytechnique Federale de Lausanne (EPFL), Anokion SA
    Inventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
  • Glycotargeting therapeutics
    Patent number: 11654188
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: May 23, 2023
    Assignees: Ecole Polytechnique Federale de Lausanne (EPFL), Anokion, SA
    Inventors: Jeffrey A. Hubbell, David Scott Wilson, Stephane Kontos, Kristen Marie Lorentz, Shuning Gai
  • GLYCOTARGETING THERAPEUTICS
    Publication number: 20230108299
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Application
    Filed: July 1, 2022
    Publication date: April 6, 2023
    Inventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
  • EPHA2 ANTIBODIES
    Publication number: 20220306752
    Abstract: Provided herein are EphA2 antibodies. These EphA2 antibodies bind preferentially to tumor tissue than normal tissue and bind to EphA2. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.
    Type: Application
    Filed: March 4, 2022
    Publication date: September 29, 2022
    Inventors: Alexander SCHOLZ, Nikhil VAD, Michael Samuel WEISS, Anne YE, Danhui ZHANG, Iraz T. AYDIN, Maryam M. BHATTI, Sean CARROLL, Jessica FINN, Shuning GAI, Shaun M. LIPPOW, Amy MANNING-BOG, Philippe MARGUET
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20220089702
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: May 2, 2018
    Publication date: March 24, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin BARBOUR, Svetlana ALEXANDER, Mark RENZ, Shuning GAI, Tarlochan S. NIJJAR, Philip James DOLAN, III, Philip PAYNE
  • Glycotargeting therapeutics
    Patent number: 10821157
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: November 3, 2020
    Assignees: ANOKION SA, ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (“EPFL”)
    Inventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
  • GLYCOTARGETING THERAPEUTICS
    Publication number: 20200121762
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 23, 2020
    Inventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
  • Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
    Patent number: 9844582
    Abstract: The present invention relates to methods of treating cancer with a combination of extended-PK IL-2 and one or more therapeutic agents, such as a therapeutic antibody. The methods of the invention are applicable across any type of cancer.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: December 19, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Karl Dane Wittrup, Byron Hua Kwan, Shuning Gai
  • GLYCOTARGETING THERAPEUTICS
    Publication number: 20160015821
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Application
    Filed: February 20, 2015
    Publication date: January 21, 2016
    Inventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
  • SYNERGISTIC TUMOR TREATMENT WITH EXTENDED-PK IL-2 AND THERAPEUTIC AGENTS
    Publication number: 20150132254
    Abstract: The present invention relates to methods of treating cancer with a combination of extended-PK IL-2 and one or more therapeutic agents, such as a therapeutic antibody. The methods of the invention are applicable across any type of cancer.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 14, 2015
    Inventors: Karl Dane Wittrup, Byron Hua Kwan, Shuning Gai
  • SYNERGISTIC TUMOR TREATMENT WITH EXTENDED-PK IL-2 AND ADOPTIVE CELL THERAPY
    Publication number: 20150017120
    Abstract: The present invention provides a method of enhancing adoptive cell therapy (ACT) by administering an extended-pharmacokinetic (PK) interleukin (IL)-2 to a cancer subject receiving ACT, optionally in combination with a therapeutic antibody. Methods of treating cancer and promoting tumor regression are also provided.
    Type: Application
    Filed: June 13, 2014
    Publication date: January 15, 2015
    Inventors: Karl Dane WITTRUP, Cary Francis OPEL, Eric Franklin ZHU, Shuning GAI